Press & Media Highlights

Healthcare Scene announces the 2026 Swaay.Health Awards, the annual recognition of standout work across healthcare marketing, PR, communications, and patient experience, with winners revealed at Swaay.Health LIVE in Foxborough. Coverage names the year's standouts across categories from Agency and Campaign of the Year to Marketer and Trailblazer, with Outcomes Rocket among the healthcare marketing community recognized in the Swaay.Health ecosystem.

LeadrPro examines how AI shortlists are reshaping B2B security demand generation, arguing that vendor consideration now happens inside answer engines before buyers ever visit a website. The article pairs G2 research on AI-mediated buying with Outcomes Rocket findings, including the 29.1 percent of organizations that cannot confirm measurable GTM impact, to make the case that source-engineering and review-site citations are the new demand-gen infrastructure.

This Abmatic AI article argues that the "ABM vs lead generation" framing is outdated, showing how the two work together in 2026 with lead gen as the discovery layer and ABM as the conversion layer, both feeding off shared intent and identity signals. It walks through how account-based lead generation works today, from finding in-market accounts through intent and visitor identification to mapping the buying committee and routing the right contact to sales at the right moment.

Outcomes Rocket CEO, Saul Marquez, joins FOMO Studios for a conversation with host Tom Salemi, sharing perspective on how medtech and health tech organizations sharpen commercial impact in a market where attention is harder to win and budgets are scrutinized line by line.

Demand Gen Report featured Outcomes Rocket CEO, Saul Marquez, on B2B go-to-market strategy, drawing on the State of Account-Based Marketing report to unpack why sales and marketing alignment, GTM ownership, and AI integration remain the defining commercial challenges for healthcare marketing leaders in 2026.

Japanese sales media Rep Hub leads its weekly news roundup with the Outcomes Rocket 2026 GTM Strategy report, summarizing the 511-leader survey and the share of organizations unable to verify GTM impact for a Japanese B2B sales audience. The piece frames the findings as evidence that sales teams must redefine GTM as a revenue engine tied to pipeline quality and deal velocity, rather than a collection of departmental activities.

Outcomes Rocket was featured in Business News This Week for its 2026 State of B2B Go-to-Market Strategy report, which found that only 37% of organizations treat GTM as a true cross-functional revenue framework. The feature highlights how AI adds limited commercial value without measurement discipline — a finding directly relevant to healthtech and medtech companies building scalable go-to-market programs.

A buyer-intent data buyer's guide comparing 12 platforms across first-party, third-party, predictive, and review-site signals, with use cases spanning ABM, sales prioritization, demand gen, and churn prevention. The article references Outcomes Rocket research on ABM ROI when framing how intent data sharpens account-based programs.

A Clearout guide on B2B GTM execution cites Outcomes Rocket research showing that 30% of B2B organizations still struggle to prove their go-to-market efforts deliver measurable results — underscoring why execution discipline, not just strategy, is what separates pipeline from revenue.

Featured in AI-TechPark, Outcomes Rocket and Censinet's white paper draws on 30 healthcare leader interviews to map how AI is shifting from experimentation to operational infrastructure in 2026 — essential reading for healthtech and medtech commercial teams navigating that transition.